本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Opko Health

1.38
-0.0250-1.79%
成交量:53.34万
成交额:73.36万
市值:9.23亿
市盈率:-17.93
高:1.40
开:1.39
低:1.36
收:1.40
数据加载中...

公司资料

公司名字:
Opko Health
交易所:
NASDAQ
成立时间:
2007
员工人数:
2997
公司地址:
4400 Biscayne Boulevard,Miami,Florida,United States
邮编:
33137
传真:
- -
简介:
OPKO Health, Inc.最初于1991年10月在特拉华州注册成立。该公司是一家多元化的医疗保健公司,寻求在大型且快速增长的医疗市场中建立行业领先地位。该公司的制药业务包括美国食品药品监督管理局(Food and Drug Administration)批准的用于治疗患有3或4期慢性肾病和维生素D不足的成人继发性甲状旁腺功能亢进的Rayaldee,以及每周一次的人生长激素注射液Somatrogon,该公司已与辉瑞公司就Somatrogon的进一步开发和商业化进行合作。

董事

名称
职位
Elias A. Zerhouni
Vice Chairman of the Board and President
Jane H. Hsiao
Vice Chairman of the Board and Chief Technical Officer
Phillip Frost
Chairman of the Board and Chief Executive Officer
Gary J. Nabel
Director and Chief Innovation Officer
Steven D. Rubin
Director and Executive Vice President-Administration
Alexis Borisy
Director
Alice Lin Tsing Yu
Director
John A. Paganelli
Director
Prem A. Lachman
Director
Richard C. Pfenniger, Jr.
Director
Richard M. Krasno
Director
Roger J. Medel
Director

股东

名称
职位
Phillip Frost
Chairman of the Board and Chief Executive Officer
Adam Logal
Senior Vice President, Chief Financial Officer, Chief Accounting Officer and Treasurer
Elias A. Zerhouni
Vice Chairman of the Board and President
Gary J. Nabel
Director and Chief Innovation Officer
Jane H. Hsiao
Vice Chairman of the Board and Chief Technical Officer
Steven D. Rubin
Director and Executive Vice President-Administration